×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NBIX – neurocrine biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NBIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/22
04:22 pm
nbix
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia [TheStreet.com]
Low
Report
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia [TheStreet.com]
4/22
04:05 pm
nbix
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Low
Report
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
4/22
10:30 am
nbix
Neurocrine Biosciences (NBIX) had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an "outperform" rating on the stock.
Low
Report
Neurocrine Biosciences (NBIX) had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an "outperform" rating on the stock.
4/17
07:49 am
nbix
Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Neurocrine Biosciences (NBIX) was upgraded by Zacks Research from "strong sell" to "hold".
4/16
10:31 pm
nbix
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]
Medium
Report
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR [Yahoo! Finance]
4/16
08:31 pm
nbix
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? [Yahoo! Finance]
Medium
Report
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? [Yahoo! Finance]
4/14
04:38 pm
nbix
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [Yahoo! Finance]
4/14
04:17 pm
nbix
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [TheStreet.com]
Low
Report
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results [TheStreet.com]
Date
Time
Symbol
Company Name
Action
%Chg
2/11/2026
04:01 pm
NBIX
neurocrine biosciences, inc.
BEAT
Report
-10.4%
neurocrine biosciences, inc.
10/28/2025
04:01 pm
NBIX
neurocrine biosciences, inc.
BEAT
Report
-6.4%
neurocrine biosciences, inc.
7/30/2025
04:01 pm
NBIX
neurocrine biosciences, inc.
BEAT
Report
-6.2%
neurocrine biosciences, inc.
5/5/2025
04:01 pm
NBIX
neurocrine biosciences, inc.
BEAT
Report
8.4%
neurocrine biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/15
04:18 pm
nbix
Form DEFA14A NEUROCRINE BIOSCIENCES
Medium
Report
Form DEFA14A NEUROCRINE BIOSCIENCES
4/15
04:18 pm
nbix
Form ARS NEUROCRINE BIOSCIENCES For: Dec 31
Medium
Report
Form ARS NEUROCRINE BIOSCIENCES For: Dec 31
4/15
04:16 pm
nbix
Form DEF 14A NEUROCRINE BIOSCIENCES For: Apr 15
Medium
Report
Form DEF 14A NEUROCRINE BIOSCIENCES For: Apr 15
4/6
07:35 am
nbix
Form 8-K NEUROCRINE BIOSCIENCES For: Apr 05
Low
Report
Form 8-K NEUROCRINE BIOSCIENCES For: Apr 05
3/27
10:51 am
nbix
Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: VANGUARD GROUP INC
3/17
05:57 pm
nbix
Form 3 NEUROCRINE BIOSCIENCES For: Mar 15 Filed by: Ratz Andrew
Neutral
Report
Form 3 NEUROCRINE BIOSCIENCES For: Mar 15 Filed by: Ratz Andrew
3/5
06:19 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Mar 04 Filed by: ABERNETHY MATT
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Mar 04 Filed by: ABERNETHY MATT
2/23
07:12 pm
nbix
Form 4 NEUROCRINE BIOSCIENCES For: Feb 20 Filed by: Onyia Jude
Low
Report
Form 4 NEUROCRINE BIOSCIENCES For: Feb 20 Filed by: Onyia Jude
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/29
Q2/2019 6/30/2019 EPS 0.540 ZacksConsensus 0.270 ActVsEst 0.270 - Beat
10.3%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
11/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
5/29 Form 4 NEUROCRINE BIOSCIENCES For: May 24 Filed by: Bozigian Haig P. 5.2%
3/25 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.6%
4/17 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.9%
8/8 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.6%
10/16 Form 4 NEUROCRINE BIOSCIENCES For: Oct 14 Filed by: Lloyd-Smith Malcolm 3.3%
7/8 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results 3.2%
5/7 Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 3.0%
1/28 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 3.0%
TOP News Decliners
1/10
Form 4 NEUROCRINE BIOSCIENCES For: Jan 08 Filed by: ROBERTS EIRY
-8.1%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
7/31 Form 4 NEUROCRINE BIOSCIENCES For: Jul 30 Filed by: Bozigian Haig P. -4.5%
4/30 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at William Blair. -3.8%
2/24 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. -3.8%
6/4 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock. -3.7%
5/17 Form 3 NEUROCRINE BIOSCIENCES For: May 07 Filed by: Cooke Julie -3.3%
4/30 Form 4 NEUROCRINE BIOSCIENCES For: Apr 28 Filed by: ABERNETHY MATT -3.3%
4/27 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -3.0%
2/4 Q4/2019 12/31/2019 EPS 1.050 ZacksConsensus 0.820 ActVsEst 0.230 - Beat -2.9%
8/8 Form 4 NEUROCRINE BIOSCIENCES For: Aug 06 Filed by: GORMAN KEVIN CHARLES -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: